A retrospective study on the therapeutic effect of tocilizumab on COVID-19
Not Applicable
Recruiting
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000040614
- Lead Sponsor
- Japanese Red Cross Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Cases where tocilizumab administration was judged to be inappropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival rate
- Secondary Outcome Measures
Name Time Method 1) Time until the RT-PCR becomes negative in the pharyngeal swab or nasopharyngeal swab (calculated for the first hospitalization date, symptom onset date, and diagnosis date) 2) Fever duration 3) Improvement rate of image findings 4) Number of days until improvement of image findings is confirmed 5) Time required until each of supplemental oxygen / non-invasive ventilation or high-flow oxygen therapy (Nasal high flow) / invasive mechanical ventilation by endotracheal intubation / ECMO (starting date: 1st hospitalization date), Symptom occurrence date, and, Diagnosis date are calculated respectively), the number of days of implementation 6) Hospitalization days 7) Survival period (calculation dates are calculated for 1st hospitalization, 2nd symptom onset, and 3rd diagnosis) Exploratory analysis: 1) Predictors of treatment effect 2) Clinical course, age, sex, medical history, smoking history, complications, blood sampling test results, therapeutic agents other than tocilizumab